City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
The announcement follows FDA 510(k) clearance of device
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
The investment will accelerate the overall Sarclisa development program
Macitentan tablets, 10 mg have an estimated market size of US $ 797 million for twelve months ending Dec 2021 according to IQVIA
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Subscribe To Our Newsletter & Stay Updated
